Deal of the Day — limited-time pharmacy picks!
Ryzodeg Penfill 100 Iu/ml 3 ml Cartridge

Ryzodeg Penfill 100 Iu/ml 3 ml Cartridge

Prescription requiredRx Required
Refrigerated 2–8°C · Online payment only

Salt Composition: Insulin Degludec (2.56mg/1ml) + Insulin Aspart (1.05mg/1ml)

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

5 Cartridge

About The Product

Combination insulin for all-day and meal-time sugar control.

Description

Ryzodeg penfill 100 IU/ML 3 MI cartridge is an insulin combination medicine. It is used to control blood sugar level in patients with diabetes mellitus. Its contains two drug formation Insulin Degludec (2.56mg/ml), a long lasting insulin that provides basal blood sugar control and Insulin Aspart (1.05mg/1ml), a rapid acting insulin that controls blood sugar after meals.

It belongs to the drug class of combination insulin analogs that helps to improve blood sugar level by providing both basal and postprandial insulin, mimicking natural insulin secretion. Doctor prescription is mandatory while using the medication to ensure safe and effective treatment option.

​

Uses

  • Manage blood sugar level

Side Effects

  • Each medication has several side effects that are harmful to the body if not treated early.
  • Patients also experience various symptoms while using Ryzodeg penfill 100 IU/ML 3 MI cartridge but they are manageable with the treatment.
  • Consult the doctor if any of the symptoms may persist or worsen: • Nausea • Vomiting • Abdominal pain • Constipation • Diarrhea • Decreased appetite • Allergic reaction (swelling, rash and difficulty in breathing)

How To Use

  • Ryzodeg penfil cartridge is administered by subcutaneous injection under the skin. It is usually injected once or twice daily based on patient treatment outcomes, preferably with meals as prescribed by the doctor.
  • Injection rotation must be thigh, abdomen, or upper arm to prevent skin problems. Do not self administer without consultation to a healthcare specialist.
    ​​

How It Works

  • Ryzodeg penfill Cartridge provides dual action insulin control as Insulin Aspart, controls blood sugar level after meals and Insulin Degludec provides steady long lasting blood sugar control for upto 24 hours.
  • Togethter they ensure rapid and consistent sugar control by facilitating the reuptake of sugar in muscle and fat cells, and suppressing the sugar in the liver.
    ​

Safety Advice

Alcohol
Ryzodeg penfill cartridge should be taken by avoiding alcohol consumption. As it can interrupt the treatment outcomes.
Pregnancy
Dose adjustment should be recommended by the healthcare professional. Ryzodeg penfill cartridge does not cause any harmful effects but still doctor guidance is needed.
Breast Feeding
Breastfeeding the baby is generally safe. Patient can use Ryzodeg penfill cartridge under doctor prescription.
Driving
Ryzodeg penfill cartridge may cause dizziness and weakness. Do not drive or operate machinery while using the medication.
Kidney
Ryzodeg penfill 100IU need dose adjustment in kidney patients to avoid complications during the treatment.
Liver
Ryzodeg penfill 100IU should be used by liver patients under doctor guidance. Healthcare professional prescribed the dosage based on the patient's medical history.

FAQs

Ryzodeg penfill cartridge manage blood sugar in patients with type 1 and type 2 both diabetes mellitus in children and adults.​

References

• Vora, J., Cariou, B., Evans, M., Gross, J. L., Harris, S., Landstedt-Hallin, L., ... & Meneghini, L.

(2015). Clinical use of insulin degludec.

Diabetes research and clinical practice, 109(1), 19-31. https://pubmed.ncbi.nlm.nih.gov/25963320/ • Haahr, H., & Heise, T. (2014).

A review of the pharmacological properties of insulin degludec and their clinical relevance. Clinical pharmacokinetics, 53(9), 787-800. https://pubmed.ncbi.nlm.nih.gov/25179915/ • Gough, S.

C. L., Harris, S., Woo, V., & Davies, M.

(2013). Insulin degludec: overview of a novel ultra long‐acting basal insulin.

Diabetes, Obesity and Metabolism, 15(4), 301-309. https://pubmed.ncbi.nlm.nih.gov/23240573/ • Evans, M., Ceriello, A., Danne, T., De Block, C., DeVries, J. H., Lind, M., ... & Wilmot, E.

G. (2019).

Use of fast‐acting insulin aspart in insulin pump therapy in clinical practice. Diabetes, Obesity and Metabolism, 21(9), 2039-2047. https://pubmed.ncbi.nlm.nih.gov/31144428/ • Haahr, H., & Heise, T.

(2020). Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences.

Clinical Pharmacokinetics, 59(2), 155-172. https://pubmed.ncbi.nlm.nih.gov/31667789/​​

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026